Endocrine Abstracts

Introduction: Sexual dysfunction is more prevalent in postmenopausal women with diabetes mellitus.

Objective: The aim of the study was to prospectively evaluate the effects of oral estradiol+drospirenone on sexual function in postmenopausal women with type 2 diabetes mellitus.

Methods: The study included 86 postmenopausal women with type 2 diabetes mellitus who were randomized into two groups: 44 women received oral 17β-estradiol+drospirenone daily and 42 women received no treatment as served as a control group. Sexual function was evaluated with a detailed 34-item questionnaire, a sexual function questionnaire.

Results: After 6 months a high probability of sexual dysfunction was present in 26.19 vs 45.2% before the treatment (P<0.001). There were no significant changes in the control group. The highest improvement was achieved in libido score: from 12.5±7.3 to 18.7±5.67 in hormonal therapy group and decreased from 13.2±8.5 to 5.7±6.43 in the control group (P=0.000 and P=0.000, respectively). There was no association between probability of sexual dysfunction and HbA1c. Conclusions: Hormonal therapy provided significant improvement in sexual function in postmenopausal women with type 2 diabetes mellitus.

Keywords: sexual function, diabetes mellitus, postmenopausal women.